Story thread · 2 reports / 2 sources
Karyopharm pushes off debt payment; Amgen eyes broader Imdelltra use
biopharmadive.com · 3d
How the coverage leans
Across 2 sources · syndicated copies counted once
Karyopharm bought an extra month to negotiate with creditors or pursue a deal. Elsewhere, BridgeBio Pharma’s oncology spinout shook up its development plans and a brain-focused gene therapy startup banked $275 million.
First report: Karyopharm pushes off debt payment; Amgen eyes broader Imdelltra use — finance.yahoo.com, 4d
The conversation · 0
Sign in to join the conversation.
No comments yet — start the thread.